Luis Bird, MD
Psychiatry · Philadelphia, PANPI 1538222658
Payments from drug & device makers
Across 530 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- Johnson & Johnson$2K
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$996
- Teva Pharmaceuticals USA, Inc.$856
- Neurocrine Biosciences, Inc.$799
- plus $4K from 14 others
What the payments were for
- Food & beverage$10,737100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 68 | $1,552 |
| Johnson & Johnson | 53 | $1,514 |
| Otsuka America Pharmaceutical, Inc. | 67 | $1,473 |
| AbbVie(2 entities) | 59 | $996 |
| Teva Pharmaceuticals USA, Inc. | 50 | $856 |
| Neurocrine Biosciences, Inc. | 29 | $799 |
| Lundbeck LLC | 44 | $755 |
| Vanda Pharmaceuticals Inc. | 30 | $677 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 35 | $548 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $490 |
| Sunovion Pharmaceuticals Inc. | 30 | $466 |
| Indivior Inc. | 17 | $345 |
| Avanir Pharmaceuticals, Inc. | 4 | $67 |
| Noven Therapeutics, LLC | 5 | $67 |
| Tempus AI, Inc | 2 | $44 |
| Braeburn Inc. | 2 | $30 |
| Neuronetics, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Almatica Pharma LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$976
- INGREZZA$330
- ABILIFY MAINTENA$247
- ARISTADA INITIO$244
- INVEGA SUSTENNA$182
- Austedo XR$101
How this compares
$10,758 in reported general payments places this provider in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 26 | $86,510 |
| Abilify MaintenaAripiprazole | 30 | $86,080 |
| RexultiBrexpiprazole | 45 | $63,731 |
| TrintellixVortioxetine Hydrobromide | 95 | $45,081 |
| CaplytaLumateperone Tosylate | 21 | $35,134 |
| LybalviOlanzapine/Samidorphan Malate | 22 | $34,385 |
| VraylarCariprazine Hcl | 22 | $30,185 |
| Aripiprazole | 195 | $17,579 |
| Lurasidone Hcl | 42 | $10,747 |
| Mirtazapine | 429 | $8,305 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $7,338 |
| IntunivGuanfacine Hcl | 12 | $7,244 |
| Buspirone Hcl | 323 | $5,763 |
| Quetiapine Fumarate | 314 | $5,638 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $5,440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,473 | $149,81175 claims |
| Johnson & JohnsonInvega Sustenna | $1,514 | $86,51026 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $490 | $45,08195 claims |
| AbbVieVraylar, Namzaric | $996 | $37,52334 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $548 | $35,13421 claims |
| Alkermes, Inc.Lybalvi | $1,552 | $34,38522 claims |
| Indivior Inc.Suboxone | $345 | $5,44011 claims |
| Almatica Pharma LLCSertraline Hcl | $15 | $1,821232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Philadelphia
- Steven ArnoldPhiladelphia$4.1M
- Michael ThasePhiladelphia$2.2M
- Daniel WeintraubPhiladelphia$647K
- Yvette ShelinePhiladelphia$442K
- Kyle KampmanPhiladelphia$355K
- Christian KohlerPhiladelphia$172K
- Freddy AliPhiladelphia$107K
- Stanley CaroffPhiladelphia$105K
- Richard JaffePhiladelphia$101K
- Ramesh EluriPhiladelphia$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.